KL-6 Mucin as Serum Tumor Marker of Metastatic Renal Cancer: A Case Report
We encountered a case of metastatic renal cell carcinoma in which the serum level of KL-6, a therapeutic marker, was exceptionally high and fluctuated with the progression of treatment. A 74-year-old man was diagnosed with right renal cystic cancer and multiple metastases in October 2022. The KL-6 l...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-01-01
|
| Series: | Case Reports in Urology |
| Online Access: | http://dx.doi.org/10.1155/2024/6648459 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832569130508615680 |
|---|---|
| author | Kyohei Ishida Go Hasegawa Toshinori Takada Akira Ogose Gen Kawaguchi Yohei Ikeda Hiroki Nishiyama Noboru Hara Tsutomu Nishiyama |
| author_facet | Kyohei Ishida Go Hasegawa Toshinori Takada Akira Ogose Gen Kawaguchi Yohei Ikeda Hiroki Nishiyama Noboru Hara Tsutomu Nishiyama |
| author_sort | Kyohei Ishida |
| collection | DOAJ |
| description | We encountered a case of metastatic renal cell carcinoma in which the serum level of KL-6, a therapeutic marker, was exceptionally high and fluctuated with the progression of treatment. A 74-year-old man was diagnosed with right renal cystic cancer and multiple metastases in October 2022. The KL-6 level was 27490 U/mL. He started treatment with lenvatinib and pembrolizumab. KL-6 decreased to 3885 U/mg in February 2023. The patient’s proteinuria worsened, leading to the discontinuation of lenvatinib. KL-6 increased to 25950 U/mL in April. He discontinued pembrolizumab and started taking cabozantinib. In September, drug-induced bilateral inflammatory pneumonitis developed. He discontinued cabozantinb and began taking axitinib. KL-6 decreased; however, he suffered from severe diarrhea and subsequent renal insufficiency. He discontinued axitinib in November. KL-6 increased to 29640 U/mL in December. |
| format | Article |
| id | doaj-art-7fd0cb3292044d61b2b9773212febe16 |
| institution | Kabale University |
| issn | 2090-6978 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Urology |
| spelling | doaj-art-7fd0cb3292044d61b2b9773212febe162025-02-02T23:11:11ZengWileyCase Reports in Urology2090-69782024-01-01202410.1155/2024/6648459KL-6 Mucin as Serum Tumor Marker of Metastatic Renal Cancer: A Case ReportKyohei Ishida0Go Hasegawa1Toshinori Takada2Akira Ogose3Gen Kawaguchi4Yohei Ikeda5Hiroki Nishiyama6Noboru Hara7Tsutomu Nishiyama8Department of UrologyDepartment of PathologyDepartment of Respiratory MedicineDepartment of Orthopedic SurgeryDepartment of Radiation OncologyDepartment of Diagnostic RadiologyDepartment of UrologyDepartment of UrologyDepartment of UrologyWe encountered a case of metastatic renal cell carcinoma in which the serum level of KL-6, a therapeutic marker, was exceptionally high and fluctuated with the progression of treatment. A 74-year-old man was diagnosed with right renal cystic cancer and multiple metastases in October 2022. The KL-6 level was 27490 U/mL. He started treatment with lenvatinib and pembrolizumab. KL-6 decreased to 3885 U/mg in February 2023. The patient’s proteinuria worsened, leading to the discontinuation of lenvatinib. KL-6 increased to 25950 U/mL in April. He discontinued pembrolizumab and started taking cabozantinib. In September, drug-induced bilateral inflammatory pneumonitis developed. He discontinued cabozantinb and began taking axitinib. KL-6 decreased; however, he suffered from severe diarrhea and subsequent renal insufficiency. He discontinued axitinib in November. KL-6 increased to 29640 U/mL in December.http://dx.doi.org/10.1155/2024/6648459 |
| spellingShingle | Kyohei Ishida Go Hasegawa Toshinori Takada Akira Ogose Gen Kawaguchi Yohei Ikeda Hiroki Nishiyama Noboru Hara Tsutomu Nishiyama KL-6 Mucin as Serum Tumor Marker of Metastatic Renal Cancer: A Case Report Case Reports in Urology |
| title | KL-6 Mucin as Serum Tumor Marker of Metastatic Renal Cancer: A Case Report |
| title_full | KL-6 Mucin as Serum Tumor Marker of Metastatic Renal Cancer: A Case Report |
| title_fullStr | KL-6 Mucin as Serum Tumor Marker of Metastatic Renal Cancer: A Case Report |
| title_full_unstemmed | KL-6 Mucin as Serum Tumor Marker of Metastatic Renal Cancer: A Case Report |
| title_short | KL-6 Mucin as Serum Tumor Marker of Metastatic Renal Cancer: A Case Report |
| title_sort | kl 6 mucin as serum tumor marker of metastatic renal cancer a case report |
| url | http://dx.doi.org/10.1155/2024/6648459 |
| work_keys_str_mv | AT kyoheiishida kl6mucinasserumtumormarkerofmetastaticrenalcanceracasereport AT gohasegawa kl6mucinasserumtumormarkerofmetastaticrenalcanceracasereport AT toshinoritakada kl6mucinasserumtumormarkerofmetastaticrenalcanceracasereport AT akiraogose kl6mucinasserumtumormarkerofmetastaticrenalcanceracasereport AT genkawaguchi kl6mucinasserumtumormarkerofmetastaticrenalcanceracasereport AT yoheiikeda kl6mucinasserumtumormarkerofmetastaticrenalcanceracasereport AT hirokinishiyama kl6mucinasserumtumormarkerofmetastaticrenalcanceracasereport AT noboruhara kl6mucinasserumtumormarkerofmetastaticrenalcanceracasereport AT tsutomunishiyama kl6mucinasserumtumormarkerofmetastaticrenalcanceracasereport |